The influence of anti-VEGF therapy on present day management of macular edema due to BRVO and CRVO: a longitudinal analysis on visual function, injection time interval and complications

International Ophthalmology

Volumn 34, Issue 6, 2014, Pages 1193-1201

  Papadia, Marina ^a,b   Misteli, Marie ^a   Jeannin, Bruno ^a   Herbort, Carl P ^a,c  

^a Centre for Ophthalmic Specialized Care (COS)   (Switzerland)

^b Ospedale Padre Antero Micone   (Italy)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Bevacizumab; Branch retinal vein occlusion (BRVO); Central retinal vein occlusion (CRVO); Fluorescein angiography (FA); Individual injection time interval; Microperimetry (MP); Optical coherence tomography (OCT)

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; ANGIOGRAPHY; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; EYE EXAMINATION; FEMALE; FLUORANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; LONGITUDINAL STUDY; MACULAR EDEMA; MALE; MICROPERIMETRY; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; VISUAL ACUITY; VISUAL FIELD; AGED; ANTAGONISTS AND INHIBITORS; COMPLICATION; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; RETINAL VEIN OCCLUSION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; LONGITUDINAL STUDIES; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84922079913     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-014-0002-1     Document Type: Article

References (39)

1. Yau JW, Lee P, Wong TY, Best J, Jenkins A (2008) Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J. 38(12):904–910
2. Royal College of Ophthalmologists. Retinal vein occlusion guidelines. Royal College of Ophthalmologists Web site. http://www.rcophth.ac.uk/docs/publications/published-guidelines/RVO_Guidelines_Feb_2009.pdf. Accessed 30 July 2009
3. Klein R, Klein BE, Moss SE, Meuer SM (2000) The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 98:133–141
4. The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98:271–282
5. The Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486–491
6. Finkelstein D (1996) Laser therapy for central retinal vein obstruction. Curr Opin Ophthalmol 7(3):80–83
7. Opremcak EM, Bruce RA, Lomeo MD, Ridenour CD, Letson AD, Rehmar AJ (2001) Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina 21(5):408–415
8. Chung EJ, Lee H, Koh HJ (2008) Arteriovenous crossing sheathotomy versus intravitreal triamcinolone acetonide injection for treatment of macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246(7):967–974
9. Weiss JN, Bynoe LA (2001) Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology 108(12):2249–2257
10. Schumann M, Hansen LL, Janknecht P, Witschel H (1993) Isovolemic hemodilution in central retinal vein occlusion in patients less than 50 years of age. Klin Monbl Augenheilkd 203(5):341–346
11. Parodi MB (2004) Medical treatment of retinal vein occlusions. Semin Ophthalmol 19(1–2):43–48
12. Asano S, Miyake K, Miyake S, Ota I (2007) Relationship between blood-aqueous barrier disruption and ischemic macular edema in patients with branch or central retinal vein occlusion: effects of sub-tenon triamcinolone acetonide injection. J Ocul Pharmacol Ther 23(6):577–584
13. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E (2002) Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 86(2):247–248
14. Ip MS, Kumar KS (2002) Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion. Arch Ophthalmol 120(9):1217–1219
15. Jonas JB, Kreissig I, Degenring RF (2002) Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 240(9):782–783
16. Kaiser PK (2005) Steroids for branch retinal vein occlusion. Am J Ophthalmol 139(6):1095–1096
17. Kiddee W, Trope GE, Sheng L, Beltran-Agullo L, Smith M, Strungaru MH, Baath J, Buys YM (2013) Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol 58(4):291–310
18. Carnahan MC, Goldstein DA (2000) Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 11(6):478–483
19. Thompson JT (2006) Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol 141(4):629–637
20. Stahl A, Agostini H, Hansen LL, Feltgen N (2007) Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 245(10):1429–1436
21. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ (2008) Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246(1):81–87
22. Hayreh SS (1983) Classification of central retinal vein occlusion. Ophthalmology 90(5):458–474
23. Glacet-Bernard A, Mahdavi KN, Coscas G, Zourdani A, Fardeau C (1994) Macular grid photocoagulation in persistent macular edema due to central retinal vein occlusion. Eur J Ophthalmol. 4(3):166–174
24. Parodi MB, Di Stefano G, Ravalico G (2008) Grid laser treatment for exudative retinal detachment secondary to ischemic branch retinal vein occlusion. Retina 28(1):97–102
25. McIntosh RL, Mohamed Q, Saw SM, Wong TY (2007) Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 114(5):835–854 Epub 2007 Mar 30
26. Ohashi H, Oh H, Nishiwaki H, Nonaka A, Takagi H (2004) Delayed absorption of macular edema accompanying serous retinal detachment after grid laser treatment in patients with branch retinal vein occlusion. Ophthalmology 111(11):2050–2056
27. Mohamed Q, McIntosh RL, Saw SM, Wong TY (2007) Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 114(3):507-19, 524
28. The Central Vein Occlusion Study Group (1995) Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The central vein occlusion study group M report. Ophthalmology 102:1425–1433
29. Russo V, Barone A, Conte E, Prascina F, Stella A et al. (2009) Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina (Phila, Pa) 29: 511–515
30. Smith GC, Pell JP (2003) Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 327(7429):1459–1461
31. Mitry D, Bunce C, Charteris D (2013) Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev 31:1
32. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118(8):1594–1602
33. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G et al (2012) A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One 7:e42701
34. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L (2014) Patel A; RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN Study. Ophthalmology 121(1):209–219
35. Epstein DL, Algvere PV, Von Wendt G, Seregard S, Kvanta A (2012) Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 119:2587–2591
36. Gokce G, Sobaci G, Durukan AH, Erdurman FC (2013) Intravitreal triamcinolone acetonide compared with bevacizumab for the treatment of patients with macular edema secondary to central retinal vein occlusion. Postgrad Med 125(5):51–58
37. Joshi L, Yaganti S, Gemenetzi M, Lightman S, Lindfield D, Liolios V, Menezo V, Shao E, Taylor SR (2013) Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol 97(8):1040–1044
38. Dunavoelgyi R, Sacu S, Eibenberger K, Palkovits S, Leydolt C, Pruente C, Schmidt-Erfurth U (2012) Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results. Retina 32(8):1471–1479
39. Yuan A, Ahmad BU, Xu D, Singh RP, Kaiser PK, Martin DF, Sears JE, Schachat AP, Ehlers JP (2014) Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Int J Ophthalmol 7(1):86–91